Therefore, our data suggest that BMP9 plays a role in the pathophysiology of HTN and CHD, and circulating BMP9 is likely to be a biomarker for the progress of HTN, CHD and HTN + CHD. This evidence concerns the gene GDF2 and coronary artery disorder.